|
|
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study
Louis Loschi
,
Raphaël Porcher
,
Fiorenza Barraco
,
Louis Terriou
,
Mohamad Mohty
et al.
Journal articles
hal-01885662v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03441014v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial
Arnaud Pigneux
,
Marie Béné
,
Louis-Rachid Salmi
,
Pierre-Yves Dumas
,
Jacques Delaunay
et al.
Journal articles
hal-02874606v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor
Clémence Deteix
,
Florence Mesnil
,
Sabine Furst
,
Noel Milpied
,
Ibrahim Yakoub-Agha
et al.
Journal articles
hal-02872489v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial
Arnaud Pigneux
,
Christian Récher
,
Marie C. Bene
,
Julien Asselineau
,
Ariane C. Mineur
et al.
Blood, 2015, 126 (23)
Journal articles
hal-01295674v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03623649v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|